Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADO-5030
- Development stage
- Phase 1
- Lead developer
- Adovate
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ADO-5030 is a small molecule adenosine 2B receptor (A2BR) antagonist being developed as a novel first-line therapy for asthma. The drug is designed to target the adenosine signaling pathway, which plays a key role in immune and inflammatory responses implicated in asthma pathophysiology. By antagonizing the A2B receptor, ADO-5030 aims to reduce airway inflammation and hyperresponsiveness. Preclinical studies have also shown efficacy in models of chronic pain and cancer, suggesting broader therapeutic potential. The compound was originally developed by Purnovate (a subsidiary of Adial Pharmaceuticals), with current development led by Adovate LLC following acquisition of relevant assets[1][2][5][7].
02
Targets
ADORA2B (Adenosine A2B receptor)
Beyond the preview
Go deeper on ADO-5030.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADO-5030.